Hot Stocks To Own For 2016

Hot Stocks To Own For 2016: Endo Pharmaceuticals Holdings Inc. (ENDP)

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The companys Endo Pharmaceuticals segment offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel for pain, urology, endocrinology, and oncology. Its Qualitest segment provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, womens health, and hypertension markets. The companys AMS segment offers various technology solutions comprising AMS 700 MS series, AMS 800 artificial urinary sphincter, GreenLight XPS laser system, Elevate transvaginal pelvic floor repair system, and Monarc subfascial hammock products in the areas of mens and womens health, and BPH therapy. Its HealthTronics segment provides urological services, such as lithotripsy, prostate treatment, anatomical pathology, and electron ic medical record services to urologists, hospitals, surgery centers, and clinics; and manufactures, sells, and maintains medical devices for tissue and tumor ablation. The companys products under development primarily include Aveed, an injectable testosterone preparation to treat male hypogonadism; BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain; ODM-201, an androgen receptor antagonist in Phase II clinical testing to treat castrate resistant prostate cancer; and EN3342, a polyurethane implant in Phase I/II trials for the maintenance treatment of schizophrenia in adults. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. The company was formerly known as Endo Pharmaceuticals Holdings Inc. and changed its name to Endo Health Solutions Inc. in May 2012. Endo Health Solutions Inc. was founded in 1997 and is! headquar t ered in Malvern, Pennsylvania.

Advisors' Opinion:

• [By Sean Williams]

  Is this the End-o for Aveed?
  Finally, on Thursday we have an FDA panel meeting for Endo Health Solutions' (NASDAQ: ENDP  ) Aveed, with is an extended-release male hypogonadism treatment.

• [By Dan Caplinger]

  Warner Chilcott may even turn the tables and decide to be an acquirer. Rumors that the company might be involved in a potential bid for Endo Health Solutions (NASDAQ: ENDP  ) back in February haven't panned out, but an acquisition could help the company bolster its pipeline. At the same time, though, its current debt load could make a buyout difficult from a financial perspective.

• [By John Kell]

  Endo Health Solutions Inc.(ENDP) said its fourth-quarter loss widened after the drug maker warned of a significant writedown and high litigation expenses earlier this month. Revenue missed expectations, and the company also gave a weak 2014 earnings outlook. Shares edged 4% to $78.95 premarket.

• [By Sean Williams]

  If there were ever any advice I'd wish to impart to the management at Endo Health Solutions' (NASDAQ: ENDP  ) subsidiary Endo Pharmaceuticals, it would be that sometimes it's better to walk away than keep fighting a losing battle.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-stocks-to-own-for-2016.html